<SEC-DOCUMENT>0000950170-24-034678.txt : 20240321
<SEC-HEADER>0000950170-24-034678.hdr.sgml : 20240321
<ACCEPTANCE-DATETIME>20240321160639
ACCESSION NUMBER:		0000950170-24-034678
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20240321
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240321
DATE AS OF CHANGE:		20240321

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARS Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001671858
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				811489190
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39756
		FILM NUMBER:		24771341

	BUSINESS ADDRESS:	
		STREET 1:		11682 EL CAMINO REAL, SUITE 120
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		858-771-9307

	MAIL ADDRESS:	
		STREET 1:		11682 EL CAMINO REAL, SUITE 120
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Silverback Therapeutics, Inc.
		DATE OF NAME CHANGE:	20160412
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>spry-20240321.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-03-21T13:45:55.1667+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:spry="http://ars-pharma.com/20240321" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_4ef25290-84f2-4e88-a030-5eac1b7fd25b" name="dei:EntityCentralIndexKey" contextRef="C_02845892-392d-4a99-b583-643c959c5a32">0001671858</ix:nonNumeric><ix:nonNumeric id="F_9398cf29-b795-4ef7-9ad1-4e2df1206d26" name="dei:AmendmentFlag" contextRef="C_02845892-392d-4a99-b583-643c959c5a32" format="ixt:fixed-false">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="spry-20240321.xsd"/></ix:references><ix:resources><xbrli:context id="C_02845892-392d-4a99-b583-643c959c5a32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-21</xbrli:startDate><xbrli:endDate>2024-03-21</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div class="section-group" style="margin:auto;width:6.5in;;"><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Washington, D.C. 20549</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_56d4956e-cfc7-4ce6-852d-e182a5de1253" contextRef="C_02845892-392d-4a99-b583-643c959c5a32" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">8-K</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">CURRENT REPORT</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Section 13 or 15(d)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">of the Securities Exchange Act of 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9889d42d-86b5-4b1c-9fa9-4f83b9c5f13e" contextRef="C_02845892-392d-4a99-b583-643c959c5a32" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">March 21, 2024</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Date of Report (Date of earliest event reported)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bc9872c5-3123-4459-a450-a0b9354e1870" contextRef="C_02845892-392d-4a99-b583-643c959c5a32" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;min-width:fit-content;">ARS Pharmaceuticals, Inc.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of registrant as specified in its charter)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:34%;"/>
     <td style="width:1%;"/>
     <td style="width:32%;"/>
     <td style="width:1%;"/>
     <td style="width:32%;"/>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_5c74d6c5-847d-4cad-b93b-0f4a93680b53" contextRef="C_02845892-392d-4a99-b583-643c959c5a32" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_7ac1cd76-0b46-4a36-bfe9-5e2861a557e9" contextRef="C_02845892-392d-4a99-b583-643c959c5a32" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">001-39756</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_41466ece-52de-4ff2-964f-24ec97e522ed" contextRef="C_02845892-392d-4a99-b583-643c959c5a32" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">81-1489190</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(State or other jurisdiction</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">of incorporation)</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Commission</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">File Number)</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(IRS Employer</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Identification No.)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:50.5%;"/>
     <td style="width:1.02%;"/>
     <td style="width:48.48%;"/>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span><ix:nonNumeric id="F_32581f44-a0f5-4aa6-9f63-92236583240e" contextRef="C_02845892-392d-4a99-b583-643c959c5a32" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">11682 El Camino Real</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_11006bf3-ba1e-45dd-b05b-9f4a43b9bc2c" contextRef="C_02845892-392d-4a99-b583-643c959c5a32" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Suite 120</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span><ix:nonNumeric id="F_e8110c30-353b-4c5d-b85a-a5755fb1fe0a" contextRef="C_02845892-392d-4a99-b583-643c959c5a32" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">San Diego</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_039fc340-673f-449b-87d4-e21eb733c3d5" contextRef="C_02845892-392d-4a99-b583-643c959c5a32" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">California</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_25785da8-01e0-4747-a5ca-3b15ca82a8a1" contextRef="C_02845892-392d-4a99-b583-643c959c5a32" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">92130</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Zip Code)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registrant&#8217;s telephone number, including area code: </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c1860c8e-3823-4b76-943a-33c078512012" contextRef="C_02845892-392d-4a99-b583-643c959c5a32" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(858)</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7cede2a8-e790-45f9-946b-b7b8fbf481e5" contextRef="C_02845892-392d-4a99-b583-643c959c5a32" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">771-9307</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not Applicable</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Former name or former address, if changed since last report.)</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:3.28%;"/>
     <td style="width:96.72%;"/>
    </tr>
    <tr style="height:11pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_502d40b6-0a62-44aa-a911-2d43eb7c8341" contextRef="C_02845892-392d-4a99-b583-643c959c5a32" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></p></td>
    </tr>
    <tr style="height:11pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_89dc8bd3-46b0-4ff0-b990-0ea71927e28d" contextRef="C_02845892-392d-4a99-b583-643c959c5a32" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p></td>
    </tr>
    <tr style="height:11pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_7a55517a-2bb0-4a02-9084-ae3d1ad0b7b5" contextRef="C_02845892-392d-4a99-b583-643c959c5a32" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></p></td>
    </tr>
    <tr style="height:11pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_7a62657d-3814-48ef-80bf-162006ebbf64" contextRef="C_02845892-392d-4a99-b583-643c959c5a32" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:34%;"/>
     <td style="width:1%;"/>
     <td style="width:32%;"/>
     <td style="width:1%;"/>
     <td style="width:32%;"/>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.007in;border-bottom:1pt solid #000000;padding-right:0.003in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title of each class</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;border-bottom:1pt solid #ffffff03;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.007in;border-bottom:1pt solid #000000;padding-right:0.003in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Trading</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Symbol(s)</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;border-bottom:1pt solid #ffffff03;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.007in;border-bottom:1pt solid #000000;padding-right:0.003in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name of each exchange</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">on which registered</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_ccafc561-596e-474b-b1b8-61faa450e9bd" contextRef="C_02845892-392d-4a99-b583-643c959c5a32" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common Stock, $0.0001 par value per share</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_ee355d24-0044-4a7c-bb61-35fa638b9de4" contextRef="C_02845892-392d-4a99-b583-643c959c5a32" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">SPRY</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_48b99e5b-aa7d-4990-b96a-b1a7c68bbf42" contextRef="C_02845892-392d-4a99-b583-643c959c5a32" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b&#8211;2 of the Securities Exchange Act of 1934 (&#167; 240.12b&#8211;2 of this chapter).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Emerging growth company </span><span style="font-size:12pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_baa39914-c877-4b4c-bf6f-d8debd53ded9" contextRef="C_02845892-392d-4a99-b583-643c959c5a32" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_b3a6bd40-bb1f-48b6-a102-c03e2abf739f" contextRef="C_02845892-392d-4a99-b583-643c959c5a32" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
   <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="s88fc7c5dc8f252f1a4d1160e76b498f0"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 2.02 Results of Operations and Financial Condition.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 21, 2024, ARS Pharmaceuticals, Inc. (the &#8220;Company&#8221;) announced its financial results for the quarter and year ended December 31, 2023 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information in this Item 2.02 of this Current Report on 8-K, including Exhibit 99.1, is furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today&#8217;s date, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:0.003472222222222222in;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:10%;"/>
     <td style="width:90%;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Item 9.01</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Financial Statements and Exhibits.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(d)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:7%;"/>
     <td style="width:4.02%;"/>
     <td style="width:88.98%;"/>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
    </tr>
    <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10.1pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99.1</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="spry-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Press Release dated March 21, 2024</span></a></p></td>
    </tr>
    <tr style="height:10.1pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
   <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:22%;"/>
     <td style="width:29.76%;"/>
     <td style="width:4%;"/>
     <td style="width:44.24%;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">ARS PHARMACEUTICALS, INC.</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: March 21, 2024</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Richard Lowenthal, M.S., MSEL</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Richard Lowenthal, M.S., MSEL</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">President and Chief Executive Officer</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
   <hr style="page-break-after:always;"/></div>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>spry-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div class="section-group" style="margin:auto;width:6.5in;;"><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 99.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img41264513_0.jpg" alt="img41264513_0.jpg" style="width:168px;height:65px;">&#160;</p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Preparing to submit response to the FDA&#x2019;s CRL for </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#174;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(epinephrine nasal spray) in Type 1 allergic reactions in early Q2 2024, following successful completion of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">repeat dose nasal allergen challenge study and nitrosamine assessments, with expected up to six-month review period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">In Phase 2 urticaria clinical trial, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> met primary endpoints and showed rapid symptom control; planning to initiate outpatient study later in 2024, potentially followed by initiation of a single pivotal efficacy study</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Ended fourth quarter with $228.4 million in cash, cash equivalents and short-term investments with an expected operating runway of at least three years; well-capitalized to support anticipated H2 2024 launch of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> in the U.S.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">SAN DIEGO -- March 21, 2024 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, today reported business updates and financial results for the fourth quarter and full year 2023.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;We started the year by turning the page and quickly addressing the two deficiencies identified in the FDA&#x2019;s CRL for </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> late last year and are now working to finalize our response to the CRL, which we expect to submit in early Q2 2024. We want to deliver this needle-free, safe, effective, and easy to carry epinephrine solution to patients in need as quickly as possible. To do so, we remain well capitalized with anticipated cash and equivalents greater than $200 million at the time of the anticipated FDA approval of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, expected in the second half of 2024,&#x201d; said Richard Lowenthal, Co-founder, President and CEO of ARS Pharma. Mr. Lowenthal further stated, &#x201c;At the recent American Academy of Allergy, Asthma &amp; Immunology (AAAAI) annual meeting in February 2024, six posters and oral presentations on </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> were presented, including efficacy data showing a 100% response rate with a single dose of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> in the 15 enrolled pediatric subjects experiencing anaphylaxis symptoms following oral food challenge, further increasing our confidence in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy&#x2019;s </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">commercial ramp and potential. At AAAAI, we also presented positive topline data from our Phase 2 inpatient, randomized, controlled study of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">in patients with refractory chronic spontaneous urticaria. </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> met all primary endpoints and showed rapid symptom control, supporting advancement to an outpatient study in chronic spontaneous urticaria patients who experience acute exacerbations of symptoms, which we plan to initiate later in 2024, followed by a potential pivotal study in 2025.&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">U.S. Regulatory Status of neffy</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(epinephrine nasal spray) for Type I Allergic Reactions</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p><div style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.5235502658900995%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In September 2023, ARS Pharma announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding its New Drug Application (NDA) for </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. In the CRL, the FDA requested completion of a pharmacokinetic (PK) / pharmacodynamic (PD) study assessing repeat doses of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> compared to repeat doses of an epinephrine injection product under allergen-induced allergic rhinitis conditions to support approval.</font></div></div><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
   <hr style="page-break-after:always;"><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div><div style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.5235502658900995%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In February 2024, ARS Pharma announced the successful completion of the repeat dosing study of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> in seasonal allergic rhinitis under nasal allergen challenge conditions. ARS Pharma also completed the nitrosamine testing requested in the CRL per the FDA&#x2019;s draft guidance issued in August 2023, with no measurable levels of nitrosamines detected. </font></div></div><div style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.5235502658900995%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The favorable topline results from this repeat dose study, meant to represent a challenging nasal scenario that is potentially relevant to less than 0.5% of patients, showed repeat doses of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> demonstrated a PK profile greater than or similar to repeat doses of intramuscular injection of epinephrine, and a PD profile greater than injection. In particular, repeat dosing in the same nostril was greater in exposure than dosing once in each nostril and greater than injection on both PK exposures and PD response at all time points, which may help inform labeling and instructions for use.</font></div></div><div style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.5235502658900995%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Having addressed the deficiencies identified by the FDA, ARS Pharma is finalizing its response to the CRL, which it expects to submit in early Q2 2024. Following an expected up to six-month review period, ARS Pharma anticipates an FDA action date and potential launch in the second half of 2024.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical Status of neffy</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">for Urticaria</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p><div style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.5235502658900995%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In late-February, ARS Pharma announced positive clinical data from a Phase 2 trial evaluating </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> in adults with chronic spontaneous urticaria. </font></div></div><div style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.5235502658900995%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">There are currently no approved community use treatments for acute flares experienced by urticaria patients on chronic regimens of antihistamines or biologics. </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> may provide episodic symptomatic relief of these acute flares or exacerbations to improve the quality of life of urticaria patients. Patients would have the option to quickly resolve exacerbations or flares at home without escalating to chronic use of systemic biologics or immunosuppressants that may have more serious side effects and benefit-risk considerations, or having to visit the emergency room for further treatment.</font></div></div><div style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.5235502658900995%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Phase 2, randomized, placebo-controlled, cross-over study in 18 adults with chronic spontaneous urticaria who were treated at the clinical site, met its primary endpoints with both 1 mg and 2 mg </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">demonstrating statistically significant and clinically meaningful improvement in pruritus, hives, body surface area and erythema from baseline as early as 5 minutes after dosing. These data were presented in an oral session at the 2024 AAAAI annual meeting.</font></div></div><div style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.5235502658900995%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARS Pharma plans to initiate an outpatient urticaria study in patients treated with antihistamines who experience frequent acute flares later in 2024, potentially followed by initiation of a single pivotal efficacy study.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Additional Business Updates and Anticipated Milestones</font></p><div style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.5235502658900995%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Marketing authorization application (MAA) for </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">is under review by the European Medicines Agency (EMA) with a decision now expected in mid-2024. Submissions to other regulatory authorities in additional countries are planned for 2024. </font></div></div><div style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.5235502658900995%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">On March 7, 2024, ARS Pharma held a virtual </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Investor Day. The ARS Pharma management team was joined by two leading allergists, Dr. Jonathan Spergel, M.D., Ph.D. and Dr. Thomas B. Casale, M.D. A replay of the event can be accessed here.</font></div></div><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
   <hr style="page-break-after:always;"><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div><div style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.5235502658900995%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In March 2024, a new U.S. patent was issued (US 11,918,655) by the U.S. Patent and Trademark Office that covers methods of treating Type I allergic reactions, including anaphylaxis, with intranasal epinephrine formulations having a wider dose range of 0.1 to 4.0 mg epinephrine with or without absorption enhancing agents. This newly issued patent recognizes the novelty of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> and its ability to safely deliver low potent doses of epinephrine with comparable PK and PD to marketed epinephrine injectables.</font></div></div><div style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.5235502658900995%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In February 2024, ARS Pharma presented six posters and oral presentations at the 2024 AAAAI Annual Meeting, including efficacy data for </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> from two distinct clinical studies in oral food challenge induced anaphylaxis and chronic spontaneous urticaria patients. The chronic urticaria data are discussed above, and the oral food challenge induced anaphylaxis efficacy data demonstrated that 100% of the 15 enrolled pediatric patients responded to a single dose of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">with a 16-minute median time to complete resolution of symptoms. The Company expects this data will support post-marketing promotion of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, if approved.</font></div></div><div style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.5235502658900995%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, ARS Pharma presented positive results during the 2023 American College of Allergy, Asthma and Immunology meeting supporting that </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> is expected to be a safe and effective treatment option for severe allergic reactions in sub-populations including patients with upper respiratory tract infections, pediatric patients weighing greater than or equal to 30 kg and patients with varying body mass index or body weight.</font></div></div><div style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.5235502658900995%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In October 2023, ARS Pharma announced that results from the single and repeat dose clinical study of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> were published in the </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Journal of Allergy and Clinical Immunology</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The clinical study evaluated single and repeat doses of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">compared to single and repeat doses of approved injection products in healthy subjects. In November 2023, the results from the self-administration clinical study of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">were also published in the </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Journal of Allergy and Clinical Immunology: In Practice</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. </font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Fourth Quarter and Full Year 2023 Financial Results</font></p><div style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.5235502658900995%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Cash Position: </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Cash, cash equivalents and short-term investments were $228.4 million as of December 31, 2023, which ARS Pharma believes is sufficient to fund its current operating plan for at least three years.</font></div></div><div style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.5235502658900995%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">R&amp;D Expenses: </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses were $3.4 million and $20.3 million for the quarter and year ended December 31, 2023, respectively.  Total research and development expenses in 2023 increased from $18.4 million in 2022 primarily due to higher payroll costs and stock-based compensation, partially offset by a decrease in license milestone expenses.</font></div></div><div style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.5235502658900995%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">G&amp;A Expenses: </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses were $6.8 million and $47.3 million for the quarter and year ended December 31, 2023, respectively. Total general and administrative expenses in 2023 increased from $18.5 million in 2022 primarily due to</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> an </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">increase in pre-commercial launch activities, payroll costs, consulting and stock-based compensation expenses.</font></div></div><div style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.5235502658900995%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Net Loss: </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Net loss was $7.2 million and $54.4 million for the quarter and year ended December 31, 2023, respectively. <br><br></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></div></div><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
   <hr style="page-break-after:always;"><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">About Type I Allergic Reactions including Anaphylaxis</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Type I severe allergic reactions are serious and potentially life-threatening events that can occur within minutes of exposure to an allergen and require immediate treatment with epinephrine, the only FDA-approved medication for these reactions. While epinephrine autoinjectors have been shown to be highly effective, there are well published limitations that result in many patients and caregivers delaying or not administering treatment in an emergency situation. These limitations include fear of the needle, lack of portability, needle-related safety concerns, lack of reliability, and complexity of the devices. There are approximately 40 million people in the United States who experience Type I severe allergic reactions. Of those, only 3.2 million have an active epinephrine autoinjector prescription, and of those, only half consistently carry their prescribed autoinjector. Even if patients or caregivers carry an autoinjector, more than half either delay or do not administer the device when needed in an emergency.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">About Urticaria</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Urticaria is a skin disorder that causes itchy hives and/or angioedema with an annualized incidence of 5 million in the US, with about 40% becoming chronic urticaria; 50% of chronic urticaria cases are non-responsive to first-line antihistamine therapy. These non-responsive patients on stable therapy regimens can experience exacerbations or flares several times a year among acute cases, and even several times a week, including up to three or four emergency room visits per year, among chronic urticaria cases.</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Angioedema is also a co-occurring symptom in about 33 to 67% of these patients. There are currently no approved community use treatments for acute flares experienced by urticaria patients on chronic regimens of antihistamines. </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> may provide episodic symptomatic relief of these acute flares or exacerbations to improve the quality of life of urticaria patients. Patients would have the option to quickly resolve exacerbations or flares at home without escalating to chronic use of systemic biologics that may have more serious side effects and benefit-risk considerations or visiting the emergency room for further treatment.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">About ARS Pharmaceuticals, Inc.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARS Pharma is a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis. The Company is developing </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#174;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> (also referred to as ARS-1), an intranasal epinephrine product in clinical development for patients and their caregivers with Type I allergic reactions including food, medications and insect bites that could lead to life-threatening anaphylaxis. For more information, visit www.ars-pharma.com.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Forward-Looking Statements</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Statements in this press release that are not purely historical in nature are &#x201c;forward-looking statements&#x201d; within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to ARS Pharma&#x2019;s: plan to submit its response to the FDA&#x2019;s CRL early in the second quarter of 2024, with an anticipated FDA action date and launch of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, if approved, in the second half of 2024; plans to initiate an outpatient urticaria study later in 2024, potentially followed by initiation of a single pivotal efficacy study; projected operating runway; belief that it is well capitalized to support the launch of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> in the U.S., if approved; expected competitive position; belief that patients using </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, as opposed to autoinjectors, will be more likely to fill their prescriptions, carry their devices, and ultimately use their devices; the timing of the EMA&#x2019;s decision and submissions to other foreign regulatory authorities; expectation that recent chronic urticaria data and oral food challenge induced anaphylaxis efficacy data will support post-marketing promotion of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">; belief that </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> may provide episodic symptomatic relief and improve the quality of life of urticaria patients; and other statements that are not historical fact. Because such statements are subject to risks and</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
   <hr style="page-break-after:always;"><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as &#x201c;anticipate,&#x201d; &#x201c;believes,&#x201d; &#x201c;expects,&#x201d; &#x201c;plans,&#x201d; &#x201c;potential,&#x201d; &#x201c;will&#x201d; and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon ARS Pharma&#x2019;s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the ability to obtain and maintain regulatory approval for </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">; even though the FDA has stated that completion of the repeat-dose study under allergen-induced allergic rhinitis conditions for </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> will sufficiently address the agency&#x2019;s outstanding questions, there is no guarantee that new issues will not be identified which could delay or prevent the approval of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">; whether the FDA will view the results from ARS Pharma&#x2019;s repeat dose study under allergen induced allergic rhinitis conditions for </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> as successful and sufficient to support approval; the PDUFA target action date may be further delayed due to various factors outside ARS Pharma&#x2019;s control; results from clinical trials may not be indicative of results that may be observed in the future; potential safety and other complications from </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">; the labelling for </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, if approved; the scope, progress and expansion of developing and commercializing </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">; the size and growth of the market therefor and the rate and degree of market acceptance thereof vis-&agrave;-vis intramuscular injectable products; ARS Pharma&#x2019;s ability to protect its intellectual property position; uncertainties related to capital requirements; and the impact of government laws and regulations. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption &#x201c;Risk Factors&#x201d; in ARS Pharma&#x2019;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, filed with the Securities and Exchange Commission (SEC) on November 9, 2023, and in ARS Pharma&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2023, being filed with the SEC later today. This and other documents ARS Pharma files with the SEC can also be accessed on ARS Pharma&#x2019;s website at ir.ars-pharma.com by clicking on the link &#x201c;Financials &amp; Filings&#x201d; under the &#x201c;Investors &amp; Media&#x201d; tab.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The forward-looking statements included in this press release are made only as of the date hereof. ARS Pharma assumes no obligation and does not intend to update these forward-looking statements, except as required by law.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARS Investor Contact:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br>Justin Chakma</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARS Pharmaceuticals<br>justinc@ars-pharma.com</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARS Media Contact:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br>Laura O&#x2019;Neill</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Finn Partners</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Laura.oneill@finnpartners.com</font></p><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
   <hr style="page-break-after:always;"></div>
  <div class="section-group" style="margin:auto;width:7.5in;;"><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ARS Pharmaceuticals, Inc.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONSOLIDATED BALANCE SHEETS</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(In thousands, except par value and share amounts)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:66.313%;"></td>
     <td style="width:1.48%;"></td>
     <td style="width:1.48%;"></td>
     <td style="width:1%;"></td>
     <td style="width:12.623000000000001%;"></td>
     <td style="width:1%;"></td>
     <td style="width:1.48%;"></td>
     <td style="width:1%;"></td>
     <td style="width:12.623000000000001%;"></td>
     <td style="width:1%;"></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</font></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</font></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current assets:</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">70,971</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">210,518</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term investments</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">157,389</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63,863</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses and other current assets</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,366</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,319</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current assets</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">231,726</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">277,700</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use asset</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">250</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">445</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fixed assets, net</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">574</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">329</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other assets</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">638</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,961</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">233,188</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">281,435</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Liabilities, convertible preferred stock and stockholders&#x2019; equity</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current liabilities:</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable and accrued liabilities (including related party amounts of $178 and $16, respectively)</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,154</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,931</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liability, current</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">237</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">230</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contract liability, current</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">283</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current liabilities</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,391</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,444</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liability, net of current portion</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">37</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">251</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contract liability, net of current portion</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,854</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,428</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,549</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commitments and contingencies</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stockholders&#x2019; equity</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Preferred stock, $0.0001 par value per share; 10,000,000 shares authorized at December 31, 2023 and 2022; no shares issued and outstanding at December 31, 2023 and 2022</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock, $0.0001 par value per share; 200,000,000 shares authorized at December 31, 2023 and 2022; 96,414,963 and 93,943,316 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additional paid-in capital</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">362,004</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">349,408</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated other comprehensive gain, net</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">407</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated deficit</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(131,303</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(76,938</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stockholders&#x2019; equity</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">230,760</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">272,886</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities, convertible preferred stock and stockholders&#x2019; equity</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">233,188</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">281,435</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
   <hr style="page-break-after:always;"><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ARS Pharmaceuticals, Inc.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(In thousands, except share and per share information)</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:75.48%;"></td>
     <td style="width:1.2%;"></td>
     <td style="width:1%;"></td>
     <td style="width:9.06%;"></td>
     <td style="width:1%;"></td>
     <td style="width:1.2%;"></td>
     <td style="width:1%;"></td>
     <td style="width:9.06%;"></td>
     <td style="width:1%;"></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</font></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</font></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</font></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenue under collaboration agreements</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,316</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses:</font></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development (including related party amounts of $1,796 and $2,144, respectively)</font></p></td>
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,266</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,376</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative (including related party amounts of $940 and $603, respectively)</font></p></td>
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">47,284</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,456</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67,550</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36,832</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss from operations</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(67,520</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(35,516</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income, net</font></p></td>
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,155</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">974</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in fair value of financial instruments</font></p></td>
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(140</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(54,365</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(34,682</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in unrealized gains and losses on available-for-sale securities</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(358</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">407</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Comprehensive loss</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(54,723</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(34,275</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per share, basic and diluted</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(0.57</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(0.87</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average shares outstanding used in computing net loss per share, basic and diluted</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">95,215,322</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39,956,043</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
   <hr style="page-break-after:always;"></div>
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img41264513_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img41264513_0.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $W R # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8$)_4FOHL^C&CAJ=*"LK_DCYO()2K8JI5F[NV_S/1J***^'/O HHHH ****
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M_H?7<-1_BR]/U%HHHKXP^V"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/[5;P_+J>MD.*]CB?9/:?Y]#]$J***_/#]'"BBB@ HHHH **** "OG;_ (*
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M@R21L,JRD=000:MU^5R;;;EN?K$4DDH[!1112*"BBB@ HHHH **** "BBB@
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MY(O5W;;/@,7URJ@"YF  P )6&/UI?[0NO^?J?_OZW^-?L[_PQA\$O^B<Z/\
M]\O_ /%4?\,8?!+_ *)SH_\ WR__ ,57A_ZP8?\ D?X?YGN_ZN8C^=?C_D?C
M%_:%U_S]3_\ ?UO\:/[0NO\ GZG_ ._K?XU^SO\ PQA\$O\ HG.C_P#?+_\
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M[CAW%7C+#2Z:K]3UBBBBOCS[0**** "BBB@ KYS_ ."@K;?V4/&(_O260_\
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M/Z5\;5^L9?4=7"TYRWL?D684U2Q=2$=KL[[]GY7D^//PX$8R_P#PD>GX_P#
MA*_="OQF_8?\)OXN_:@\$1*NZ+3[B34Y3_=6&-F4_P#?>P?C7[,5\CQ#-.O"
M/9?J?8<.0:H3GW?Y?\.+1117RI]:%%%% !1110 4444 %%%% !1110 4444
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M^6VTNQERQ[#?($4#\:_/?]IK]JCQ)^TIX@A>]3^R/#5DY:PT6&0NJ,>/-D;
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M_#O31_NR3#^3U$?V'/@8W_-/;'\+FX'_ +4KW?\ 6'#_ ,DOP_S/!_U<Q/\
M/'\?\C\L_@'^T!XG_9Y\9#7/#TJSVTX6/4-+N"?(O(P<@-C[K#)VN.02>H)!
M_1KP'_P4>^$'BFQA;6;V^\)7[#]Y;ZA:22HK>TL08$>Y"_05V!_87^!9_P":
M?68^EY=?_':9_P ,*? OK_PK^U_\#;K_ ..UY6+QV78Q\U2$E+NK?YGJX/ Y
ME@5R4YQ<>SO_ )'4>#?VHOA3\0->M-$\/^.-+U'5KLE;>S5F224@$D*&49.
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MZVWK<H/R3_Z]>R5_2'"JMDU#T?\ Z4SMI_"@HHHKZLT"BBDH 6BBB@ HHHH
M**** "BDS2T %%%% !1110 44E+0 4444 %%%% !1124 +1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MFU7%U<1A\1\3?.D^SW7HM+>IC3E>Z9T%%%%?I9N%%%% !1110 4444 %%%%
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MKB_^%R>#?^@W'_WZD_\ B:/^%R>#?^@W'_WZD_\ B:]O^ULN_P"@B'_@4?\
M,OFCW.TKY3^,/_)2-:_WX_\ T6E>\?\ "Y/!W_0;C_[]2?\ Q-?/GQ*U:TUW
MQQJE_8S"XM)G0I( 0&PB@\'GJ#7Y]QICL+B<!3A0JQD^=:)I_9EV9C5::T/H
M[X7?\D]T#_KT2NIKEOA?_P D]T#_ *]$_E74U^BY;_N5#_!'\D;QV04445Z(
MR*XN([2WEGE8)%&I=V/8 9)KQ3X,QR>+O'FO^*KA<J"5BS_"7/ _!% _&NL^
M.?B,:'X'FMD?;<:@PMEYYV]7/Y#'_ JM_!G0?[!\!V&]=L]YF[DSU^;[O_CH
M6OC<5+Z]G=#"K6-%.I+_ !/2*]5N9O6278\#^(FAOX1\=:A!!F)5F%S;,.RL
M=RX^AR/PKZ<\(>($\4>&M/U-/^7B(,Z_W7'##\"#7EW[1GA_S+73-;C3F-C:
MS'_9/*'\P1_P*D_9T\2>9;ZCH4K<QG[5 #_=/#@?C@_\"-?,Y2_[&X@K8!Z0
MJZQ_-?K'U,X^[-H]KHHHK]8.@**** /C6^_Y&JY_Z_V_]&FOLJOC74/^1JN?
M^O\ ;_T::^RJ_*^!_BQ?K'_VXYZ74*X/XW6ZW'PWU,L,F)HI%^HD4?U-=Y7F
MOQ]U9+'P(UJ6 EO9TC5>Y"G>Q_\ '1^=?<9Y.$,LQ#GMR2_%67XFL_A9YC\
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MHT)[QC%/U22-XJR2"BBBN\84444 ?,GQX.?B-<_]>T/\C7LOP9/_ !;71?\
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MM6BC+,GI93%T\-4ER-WL[-7^Z_XBC%1V"FR1K*C(RAD88*GH1Z4ZBO>+/,?
M?PC7PEXTU/5'9'M%RNGH#ED5N6SZ$#Y1[9KTZBBO/P. P^74G1PT;1;;^;_J
MR\A)*.B"F2%@C% &;' )P"?K3Z*] 9\UZC\#?%UQ>W,XMK-O.E:3:ER,#<2<
M<@>M>B>"6\>^%]+@TV^T*WU.V@79%*E\B2*HZ*<Y! _"O4**^0P?#.&R^LZ^
M%JSC)[ZQU]4XLS5-)W1RTVO>)?*S!X5S(1P)=0B4 ^^ :\G\6?#/Q[XVUA]1
MU"*R1\;(X5N?DC3^ZO'Z]Z^@:*[<?DM/,X*GB:TW%=+Q2_".HW'FT;.#^'L/
MB7P]H^GZ-J.BP^3;CR_MD%VI 3D@E2,Y^E=Y117K83#+"4HT5)R4597MLM+:
M)%)6T"BBBNP9Q/Q9\,ZAXN\+_P!G:=:PSSM,LF^:79Y>WN.#DGD?C7D.G?!O
MQQH^H07ME%;PW4#AXY$NEX/]1[5]*45\KF/#F$S+$K%5924U9*S2M;;H9R@I
M.[.2T'6/%DGD0ZOX>@B8D+)<VUZA0#NVPC/X9-=92T5]#0HRHPY95'/S=K_@
MD6@HHHKI&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
(% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>spry-20240321.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-03-21T13:45:55.5343+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://ars-pharma.com/20240321" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:spry="http://ars-pharma.com/20240321" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://ars-pharma.com/20240321/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://ars-pharma.com/20240321/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="spry-20240321.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20240321/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139744781171472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Mar. 21, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001671858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 21,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ARS Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-1489190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">11682 El Camino Real<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">771-9307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SPRY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>7
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M4$L! A0#%     @ TH!U6.26$"GN    *P(  !$              ( !KP
M &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ TH!U6)E<G",0!@  G"<
M !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M    " #2@'58PZ8'1(,$  #/$0  &               @($-"   >&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ TH!U6)^@&_"Q @  X@P
M  T              ( !Q@P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #2
M@'58EXJ[',     3 @  "P              @ &B#P  7W)E;',O+G)E;'-0
M2P$"% ,4    " #2@'58'#AEZC\!   \ @  #P              @ &+$
M>&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ TH!U6"0>FZ*M    ^ $  !H
M             ( !]Q$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!
M A0#%     @ TH!U6&60>9(9 0  SP,  !,              ( !W!(  %M#
G;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  )A0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="spry-20240321.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20240321/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="spry-20240321.htm">spry-20240321.htm</File>
    <File>spry-20240321.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "spry-20240321.htm": {
   "nsprefix": "spry",
   "nsuri": "http://ars-pharma.com/20240321",
   "dts": {
    "inline": {
     "local": [
      "spry-20240321.htm"
     ]
    },
    "schema": {
     "local": [
      "spry-20240321.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 24
   },
   "report": {
    "R1": {
     "role": "http://ars-pharma.com/20240321/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_02845892-392d-4a99-b583-643c959c5a32",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20240321.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_02845892-392d-4a99-b583-643c959c5a32",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20240321.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://ars-pharma.com/20240321/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://ars-pharma.com/20240321/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://ars-pharma.com/20240321/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://ars-pharma.com/20240321/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://ars-pharma.com/20240321/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://ars-pharma.com/20240321/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://ars-pharma.com/20240321/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://ars-pharma.com/20240321/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://ars-pharma.com/20240321/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://ars-pharma.com/20240321/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://ars-pharma.com/20240321/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://ars-pharma.com/20240321/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://ars-pharma.com/20240321/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://ars-pharma.com/20240321/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://ars-pharma.com/20240321/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://ars-pharma.com/20240321/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://ars-pharma.com/20240321/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://ars-pharma.com/20240321/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://ars-pharma.com/20240321/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://ars-pharma.com/20240321/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://ars-pharma.com/20240321/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://ars-pharma.com/20240321/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://ars-pharma.com/20240321/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://ars-pharma.com/20240321/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0000950170-24-034678-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-034678-xbrl.zip
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M.3YIBK$ Q4F)YJ? 9SPVY&((?1B<I?=A].,P3EL_*_+?\6*(;XL5\N*03J/
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M5D7/TJP1ZRE9(V^6.CO!$JDF3FG.%9'\P3F1/@A %C(_!P$8Q3+K89@QV0K
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MGS2]F(X__W32[.>#\//_ U!+ P04    " #3@'58>]$JK\4)  !=?0  $0
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MZC0Q9\VOWKT]>\VDUAEZEMBYB8@2&"-JC,,/QMW^ZOSKA]>@A(UX0I:E3,V
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MZZD&>('_%\2"3Y(4&H\G?6C9<1P6N<+(BX CFZ@$C1TPG0 I-2T<98L8E\1
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M Q5,?_W3FU_&Z23\]7\!4$L! A0#%     @ TX!U6,ZTET[Y%   S]@  !$
M             ( !     '-P<GDM,C R-# S,C$N:'1M4$L! A0#%     @
MTX!U6'O1*J_%"0  77T  !$              ( !*!4  '-P<GDM,C R-# S
M,C$N>'-D4$L! A0#%     @ TX!U6&6YK?I[*P  V)0"  \
L ( !'!\  '-P<GDM97@Y.5\Q+FAT;5!+!08      P # +L   #$2@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>spry-20240321_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="spry-20240321.xsd" xlink:type="simple"/>
    <context id="C_02845892-392d-4a99-b583-643c959c5a32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
        </entity>
        <period>
            <startDate>2024-03-21</startDate>
            <endDate>2024-03-21</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="C_02845892-392d-4a99-b583-643c959c5a32"
      id="F_4ef25290-84f2-4e88-a030-5eac1b7fd25b">0001671858</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_02845892-392d-4a99-b583-643c959c5a32"
      id="F_9398cf29-b795-4ef7-9ad1-4e2df1206d26">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="C_02845892-392d-4a99-b583-643c959c5a32"
      id="F_56d4956e-cfc7-4ce6-852d-e182a5de1253">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_02845892-392d-4a99-b583-643c959c5a32"
      id="F_9889d42d-86b5-4b1c-9fa9-4f83b9c5f13e">2024-03-21</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_02845892-392d-4a99-b583-643c959c5a32"
      id="F_bc9872c5-3123-4459-a450-a0b9354e1870">ARS Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_02845892-392d-4a99-b583-643c959c5a32"
      id="F_5c74d6c5-847d-4cad-b93b-0f4a93680b53">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_02845892-392d-4a99-b583-643c959c5a32"
      id="F_7ac1cd76-0b46-4a36-bfe9-5e2861a557e9">001-39756</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_02845892-392d-4a99-b583-643c959c5a32"
      id="F_41466ece-52de-4ff2-964f-24ec97e522ed">81-1489190</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_02845892-392d-4a99-b583-643c959c5a32"
      id="F_32581f44-a0f5-4aa6-9f63-92236583240e">11682 El Camino Real</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_02845892-392d-4a99-b583-643c959c5a32"
      id="F_11006bf3-ba1e-45dd-b05b-9f4a43b9bc2c">Suite 120</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_02845892-392d-4a99-b583-643c959c5a32"
      id="F_e8110c30-353b-4c5d-b85a-a5755fb1fe0a">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_02845892-392d-4a99-b583-643c959c5a32"
      id="F_039fc340-673f-449b-87d4-e21eb733c3d5">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_02845892-392d-4a99-b583-643c959c5a32"
      id="F_25785da8-01e0-4747-a5ca-3b15ca82a8a1">92130</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_02845892-392d-4a99-b583-643c959c5a32"
      id="F_c1860c8e-3823-4b76-943a-33c078512012">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_02845892-392d-4a99-b583-643c959c5a32"
      id="F_7cede2a8-e790-45f9-946b-b7b8fbf481e5">771-9307</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_02845892-392d-4a99-b583-643c959c5a32"
      id="F_502d40b6-0a62-44aa-a911-2d43eb7c8341">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_02845892-392d-4a99-b583-643c959c5a32"
      id="F_89dc8bd3-46b0-4ff0-b990-0ea71927e28d">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_02845892-392d-4a99-b583-643c959c5a32"
      id="F_7a55517a-2bb0-4a02-9084-ae3d1ad0b7b5">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_02845892-392d-4a99-b583-643c959c5a32"
      id="F_7a62657d-3814-48ef-80bf-162006ebbf64">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_02845892-392d-4a99-b583-643c959c5a32"
      id="F_ccafc561-596e-474b-b1b8-61faa450e9bd">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_02845892-392d-4a99-b583-643c959c5a32"
      id="F_ee355d24-0044-4a7c-bb61-35fa638b9de4">SPRY</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_02845892-392d-4a99-b583-643c959c5a32"
      id="F_48b99e5b-aa7d-4990-b96a-b1a7c68bbf42">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_02845892-392d-4a99-b583-643c959c5a32"
      id="F_baa39914-c877-4b4c-bf6f-d8debd53ded9">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_02845892-392d-4a99-b583-643c959c5a32"
      id="F_b3a6bd40-bb1f-48b6-a102-c03e2abf739f">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
